NIDCD Core for Clinical Research and Care

NIDCD 临床研究和护理核心

• 批准号: 10470081
• 负责人: CARTER VAN WAES
• 金额: $ 254.1万
• 依托单位: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10470081
• 关键词: AQP1 gene; Adjuvant Study; Administrator; Admission activity; Adult; Affect; Ambulatory Care Facilities; Appointment; Area; Audiology; Care given by nurses; Caring; Child; Chromosome Mapping; Cisplatin; Clinical; Clinical Clerkship; Clinical Data; Clinical Investigator; Clinical Research; Clinical Services; Clinical Trials; Clinics and Hospitals; Communication; Communication impairment; Complex; Consult; Consultations; Continuing Education; Credentialing; Data; Data Collection; Databases; Development; Disease; Dose; Drug Kinetics; Emergency Situation; Endoscopy; Equilibrium; Equipment and Supplies; Evaluation; Fellowship; Fostering; Genes; Genetic study; Genomics; Head Cancer; Head and Neck Cancer; Head and Neck Disorder; Head and Neck Squamous Cell Carcinoma; Head and Neck Surgeon; Hearing; Hearing problem; Hereditary Disease; Hospital Administration; Hospitals; Hour; Human; Human Papilloma Virus Vaccine; Human Papillomavirus; Human Resources; Human papilloma virus infection; Image; Immune; India; Inpatients; Institutes; Institutional Review Boards; Intervention Studies; Intramural Research Program; Laboratories; Labyrinth; Maintenance; Malignant Neoplasms; Medical; Medical Students; Mentors; Mission; Molecular; Molecular Analysis; Monitor; NF-kappa B; National Institute on Deafness and Other Communication Disorders; Natural History; Neck Cancer; Nurse Practitioners; Nursing Research; Olfactory Neuroblastoma; Operative Surgical Procedures; Otolaryngologist; Otolaryngology; Outpatients; Pakistan; Parotid Gland; Pathogenesis; Patient Care; Patient Education; Patients; Phase; Phase I/II Trial; Phenotype; Physicians; Program Development; Proteomics; Protocols documentation; Provider; Records; Recurrence; Recurrent respiratory papillomatosis; Research; Research Support; Research Training; Resectable; Resources; Safety; Salivary; Scientist; Services; Signal Transduction; Solid Neoplasm; Specimen; Speech; Supervision; Surgeon; Syndrome; Testing; Time; Training; Transforming Growth Factor beta; Travel; Triad Acrylic Resin; United States National Institutes of Health; Vaccines; Vestibular Aqueduct; Visit; Voice; Work; adeno-associated viral vector; anti-PD-L1; anti-tumor immune response; atorvastatin; career development; chemotherapy; cisplatin induced hearing loss; clinical care; clinical implementation; data management; genetic analysis; genetic deafness; genome editing; hearing impairment; hearing restoration; hereditary hearing loss; human subject; inpatient service; irradiation; meetings; neoplasm therapy; outpatient programs; patient screening; phase 1 study; phase 2 study; programs; protocol development; quality assurance; recruit; response; symposium; transcription factor; volunteer

The NIDCD Core for Clinical Research and Care supports the following NIDCD projects: 1 Z01-DC-000016 NF-kappaB in the molecular pathogenesis and therapy of Neoplasms Affecting Human Communication 1 ZIA DC000039 Identification of Genes Causing Syndromic And Nonsyndromic Hearing Impairment 1 ZIA DC000046 Genetic Studies of Human Communications Disorders 1 ZIA DC000060 Molecular Analysis Of Human Hereditary Deafness 1 ZIA DC000064 Clinical Analysis Of Disorders Of Hearing And Balance 1 ZIA-DC-000073 Signal and Transcription Factor Network Interactions in Head and Neck Cancer 1 ZIA-DC-000074 Genomics and Proteomics of Head and Neck Cancer 1 ZIA-DC-000082 Neurotology Program 1 ZIA-DC-000087 Characterization & Enhancement of Anti-tumor Immune Responses in Head & Neck Cancer 1-ZIA-DC-000088 Cellular and Molecular Pathogenesis of Hearing Restoration in Adullt Inner Ear 1-ZIA-DC-000090 Mechanisms and Optimal Combination of Cisplatin Chemotherapy for Head and Neck Cancer The NIDCD and collaborative protocols supported by the core include: OH93-DC-0016 - Nonsyndromic Hereditary Hearing Impairment Gene Mapping: India / Pakistan Protocol 97-DC-0180 - Genetic Analysis of Human Hereditary Hearing Impairment 01-DC-0228 - Clinical and Molecular Analysis of Hearing Impairment with Enlarged Vestibular Aqueducts 01-DC-0229- Genetic Analysis of Hereditary Disorders of Hearing and Balance 17-DC-0138 - Cisplatin and statins in ototoxcity 18-DC-0051 - NIDCD Biospecimens protocol 20-DC-0047 Natural History and Genome Editing in Dominant Hearing Loss 21-DC-0002 Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss 21-C-0009 A Natural History Study of Children and Adults With Olfactory Neuroblastoma 000077 Clinical Data and Specimens in head and neck disorders 000141 Hearing Instability Phenotyping 15-D-0129 Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 in Irradiation-Induced Parotid Salivary Hypofunction 19-C-0041 Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma 19-C-0002 A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis 20-C-0024 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination with TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated with Human Papillomavirus Infection 20-C-0155 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetic , Immune and Clinical Activity of SX-682 in Combination with M7824 With CV301 TRICOM in Advanced Solid Tumors 20-C-0104 Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers 21-C-0013 A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis The NIDCD Core for Clinical Research and Care supports over 3,000 outpatient clinic evaluations per year. Core otolaryngologists perform 50-100 major surgical cases annually. Staff mentor medical students during senior clinical clerkships. The Otolaryngologist Surgeon Scientist Career Development Program is coordinated through the OCD.

NIDCD临床研究和护理的核心支持以下NIDCD项目： 1 Z01-DC-000016 NF-kappab在影响人类交流的肿瘤的分子发病机理和治疗中 1 ZIA DC000039鉴定引起综合征和非综合性听力障碍的基因 1 ZIA DC000046人类通信疾病的遗传研究 1 Zia DC000060人遗传性耳聋的分子分析 1 ZIA DC000064听力和平衡疾病的临床分析 1 Zia-DC-000073头和颈癌中的信号和转录因子网络相互作用 1 Zia-DC-000074头和颈癌的基因组学和蛋白质组学 1 ZIA-DC-000082神经病学计划 1 Zia-DC-000087头颈癌的抗肿瘤免疫反应的表征和增强 1-zia-dc-000088 adullt内耳中听力恢复的细胞和分子发病机理 1-zia-dc-000090头和颈癌的顺铂化疗的机制和最佳组合 核心支持的NIDCD和协作协议包括： OH93-DC-0016-非综合性遗传性听力障碍基因映射：印度 /巴基斯坦协议 97-DC-0180-人遗传性听力障碍的遗传分析 01-DC-0228-临床和分子分析听力障碍，前庭渡槽扩大 01-DC-0229-听力和平衡的遗传性疾病的遗传分析 17-DC-0138-Ototoxcity中的顺铂和他汀类药物 18-DC-0051-NIDCD生物素质协议 20-DC-0047自然历史和基因组编辑在主要听力损失中 21-DC-0002 III期介入研究使用阿托伐他汀减少顺铂诱导的听力损失 21-C-0009儿童和成人的自然历史研究 000077头和颈部疾病中的临床数据和标本 000141听力不稳定性表型 15-D-0129剂量升级研究评估了编码人类水通道蛋白-1在辐射引起的腮腺唾液唾液功能下的腺相关病毒载体的单个给药的安全性 19-C-0041 Birinapant和强度调制的重新辐照疗法（IMRRT）用于局部复发的头部和颈部鳞状细胞癌 19-C-0002 M7824的II期研究对患有复发性呼吸乳头状瘤病的受试者 20-C-0024抗PD-L1/TGF-BETA陷阱（M7824）并与三合会疫苗和N-803结合使用，用于切除的头部和颈部鳞状细胞癌，与人乳头瘤病毒无关 20-C-0155 I/II期试验，研究了SX-682与M7824结合使用的安全性，耐受性，药代动力学，免疫和临床活性 HPV疫苗PRGN-2009单独或与抗PD-L1/TGF-BETA陷阱（M7824）组合HPV疫苗PRGN-2009的20-C-0104 I/II期试验 21-C-0013对成年患者辅助PRGN-2012的I期研究 NIDCD临床研究和护理的核心每年支持3,000多次门诊诊所评估。核心耳鼻喉科医生每年执行50-100例主要手术病例。高级临床职员期间的员工导师医学生。耳鼻喉科医生外科医生科学家职业发展计划通过强迫症协调。